butabarbital decreases outcomes of sufentanil SL by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Watch Carefully. Coadministration of CYP3A4 inducers may possibly decrease sufentanil concentrations and efficacy, probably precipitating withdrawal syndrome in people who defini